Published in J Hematol Oncol on October 08, 2015
Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma. Exp Hematol Oncol (2015) 0.95
Bispecific antibodies and their applications. J Hematol Oncol (2015) 0.92
T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget (2016) 0.81
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol (2016) 0.81
Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG. Exp Hematol Oncol (2016) 0.78
New development in CAR-T cell therapy. J Hematol Oncol (2017) 0.78
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies. Int J Mol Sci (2016) 0.77
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J Hematol Oncol (2017) 0.75
Immunotherapy in hematologic malignancies: past, present, and future. J Hematol Oncol (2017) 0.75
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. J Hematol Oncol (2017) 0.75
Molecular alterations in the TCR signaling pathway in patients with aplastic anemia. J Hematol Oncol (2016) 0.75
Redirecting T-cells to eradicate B-cell acute lymphoblastic leukemia: Bispecific T-cell engagers and chimeric antigen receptors. Leukemia (2016) 0.75
Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia - role of blinatumomab. Onco Targets Ther (2017) 0.75
CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1(+) tumor cells, and extends the survival of tumor-bearing humanized mice. Oncotarget (2017) 0.75
Recent developments in immunotherapy of acute myeloid leukemia. J Hematol Oncol (2017) 0.75
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol (2014) 4.37
Strategies for modern biomarker and drug development in oncology. J Hematol Oncol (2014) 1.89
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med (2014) 1.59
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol (2013) 1.33
Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol (2012) 1.26
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer (2015) 1.25
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol (2015) 1.17
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood (2013) 1.16
Immunotherapy of Non-Hodgkin's lymphomas. Hematology Am Soc Hematol Educ Program (2001) 1.12
Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br J Haematol (2013) 1.09
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia (2015) 1.01
Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol (2013) 1.00
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. Front Immunol (2015) 0.98
Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies. Mol Immunol (2015) 0.98
New antibody approaches to lymphoma therapy. J Hematol Oncol (2014) 0.97
Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs (2009) 0.83
Toward victory in adult ALL: blinatumomab joins in. Blood (2012) 0.83
Immune checkpoint inhibition in lymphoid disease. Br J Haematol (2015) 0.79
FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors. Oncotarget (2015) 0.81